Why would Deerfield agree to the second 4o million dollar tranche if there are any concerns with the dreamboat device? Weren't these convertible notes subject to the achievement of studies 171 and 175 meeting all primary endpoints and safety issues that would prevent approval of Afrezza ? Wouldn't they just back out if they new something was wrong? You have to think they have been in direct contact with management and would probably know a bit more then we do about clinical trial results.